Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications
- PMID: 34645480
- PMCID: PMC8511847
- DOI: 10.1186/s12954-021-00546-9
Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications
Abstract
Background: The North American opioid overdose crisis is driven in large part by the presence of unknown psychoactive adulterants in the dynamic, unregulated drug supply. We herein report the first detection of the psychoactive veterinary compound xylazine in Toronto, the largest urban center in Canada, by the city's drug checking service.
Methods: Toronto's Drug Checking Service launched in October 2019. Between then and February 2021, 2263 samples were submitted for analysis. The service is offered voluntarily at harm reduction agencies that include supervised consumption services. Samples were analyzed using gas chromatography-mass spectrometry or liquid chromatography-high resolution mass spectrometry. Targeted and/or untargeted screens for psychoactive substances were undertaken.
Results: In September 2020, xylazine was first detected by Toronto's Drug Checking Service. Among samples analyzed from September 2020 to February 2021 expected to contain fentanyl in isolation (610) or in combination with methamphetamine (16), xylazine was detected in 46 samples (7.2% and 12.5% of samples, respectively). Samples were predominantly drawn from used drug equipment. Three of the samples containing xylazine (6.5%) were associated with an overdose.
Conclusion: We present the first detection of xylazine in Toronto, North America's fourth-largest metropolitan area. The increased risk of overdose associated with use of xylazine and its detection within our setting highlights the importance of drug checking services in supporting rapid responses to the emergence of potentially harmful adulterants. These data also highlight the clinical challenges presented by the dynamic nature of unregulated drug markets and the concomitant need to establish regulatory structures to reduce their contribution to overdose morbidity and mortality.
Keywords: Adulterants; Drug checking service; Harm reduction; Mass spectrometry; Opioids; Overdose; Xylazine.
© 2021. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
References
-
- Ahmad FB, Rossen LM SP. Provisional Drug Overdose Death Counts. National Center for Health Statistics; 2021. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.
-
- Health Canada. Opioid- and Stimulant-related Harms in Canada Published:(June 2021). https://health-infobase.canada.ca/substance-related-harms/opioids-stimul.... Published 2021.
-
- Toronto Public Health. Toronto Public Health reports record high number of confirmed opioid overdose deaths in 2020. 2021. https://www.toronto.ca/news/toronto-public-health-reports-record-high-nu....
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
